NCT00002313已完成1 期
Extended Maintenance Protocol for Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection (NOTE: Continuation Study Intended Only for Patients Who Have Completed FDA 103B)
Argus Pharmaceuticals1 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 1
研究概览
简要总结
To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate the safety and potential antiviral activity of intravenous nystatin and oral didanosine (ddI) administered in an alternating regimen in this patient population.
详细描述
Patients who have completed protocol FDA 103B are offered the option of receiving extended maintenance. Patients who have received no prior ddI are treated either with intravenous nystatin alone (at the same dose level administered in FDA 103B) or with a regimen of intravenous nystatin and ddI alternating on 3-week cycles. Treatment continues for 12 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Completed 12 weeks of therapy with intravenous nystatin on protocol FDA 103B.
- •No evidence of toxicity or progression of disease on protocol FDA 103B. (See protocol FDA 103B for initial entry requirements.)
- •Active drug or alcohol abuse.
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.HIV InfectionsNCT00002097Argus Pharmaceuticals
已完成
1 期
The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected PatientsHIV InfectionsNCT00002346Gilead Sciences36
终止
2 期
The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected InfantsHIV InfectionsNCT00000961National Institute of Allergy and Infectious Diseases (NIAID)112
已完成
1 期
CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV PatientsHIV-1 InfectionsNCT01013415University of Pennsylvania17
已完成
1 期
A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their InfantsPregnancyHIV InfectionsNCT00000944National Institute of Allergy and Infectious Diseases (NIAID)24